Efficacy in angiotensin receptor blockade: A comparative review of data with olmesartan

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 10, Issue 3, 2009, Pages 147-156

  Redon, Josep ^a,b,c   Fabia, Jose Maria ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Angiotensin receptor blocker; Blood pressure; Hypertension; Olmesartan; Renin angiotensin aldosterone system

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; EPROSARTAN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ANGIOTENSIN BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; MONOTHERAPY; MORNING DOSAGE; REVIEW; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; IMIDAZOLES; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 69949095375     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320309342735     Document Type: Review

References (48)

1. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
2. Law MR, Wald NJ, Morris JK et al. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003;326:1427.
3. Yusuf S., Teo KK, Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
4. Teo K., Yusuf S., Sleight P. et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148(1):52-61.
5. Elliott WJ, Plauschinat CA, Skrepnek GH et al. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007;20(1):72-80.
6. Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
7. Parving HH, Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
8. Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
9. Lithell H., Hansson L., Skoog I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
10. McMurray JJ, Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362:767-71.
11. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
12. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
13. Basile JN, Chrysant S. The importance of early antihypertensive efficacy: The role of angiotensin II receptor blocker therapy. J Hum Hypertens 2006;20:169-75.
14. Heran BS, Wong MM, Heran IK, Wright JM Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008;4:CD003822.
15. Fabia MJ, Abdilla N., Oltra R. et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007;25:1327-36.
16. Pickering TG, White WB When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008;2:119-24.
17. Dolan E., Stanton A., Thijs L. et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension 2005;46:156-61.
18. Zannad F., Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: An overview of randomized controlled studies. Fundam Clin Pharmacol 2007;21:181-90.
19. Oparil S., Williams D., Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91, 318.
20. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002;16(suppl 2):S24-8.
21. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig 2003;23:419-30.
22. Liau CS, Lee CM, Sheu SH et al. Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in Chinese patients. Clin Drug Investig 2005;25:473-9.
23. Giles TD, Oparil S., Silfani TN et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:187-95.
24. Agabiti-Rosei E. Antihypertensive efficacy of olmesartan medoxomil compared with losartan in patients with hypertension and mild-moderate renal impairment. American Society of Hypertension, 14-17 May 2008, New Orleans, Louisiana, USA.
25. Nakayama S., Watada H., Mita T. et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008;31(1):7-13.
26. Destro M., Scabrosetti R., Vanasia A. et al. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Adv Ther 2005;22(1):32-43.
27. Rump LC, Ambrosioni E., Burnier M. et al. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 2006;20:299-301.
28. Ram CV Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: A review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004;6:569-77.
29. Fogari R., Zoppi A., Mugellini A. et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006;23:680-95.
30. Oparil S., Silfani TN, Walker JF Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens 2005;18:287-94.
31. Smith DH, Dubiel R., Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005;5(1):41-50.
32. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006;26:185-93.
33. Elliott WJ Circadian variation in blood pressure: Implications for the elderly patient. Am J Hypertens 1999;12:43S-49S.
34. Morgan T., Anderson A. How important is 24-hour control of blood pressure? Drug Saf 1996;15:243-8.
35. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12.
36. Fogari R., Mugellini A., Zoppi A. et al. Telmisartan hydrochlorothiazide combination is more effective than olmesartan hydrochlorothiazide combination in the treatment of moderate hypertension. J Clin Hypertens 2007;9(suppl A):159 (P-381).
37. Brunner HR The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002;16(suppl 2):S13-S16.
38. Julius S., Kjeldsen SE, Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-31.
39. Chrysant SG, Marbury TC, Robinson TD Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17:425-32.
40. Verdecchia P., Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther 2004;26:460-72.
41. Jones MR, Sealey JE, Laragh JH Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007;20:907-16.
42. Hasler C., Nussberger J., Maillard M. et al. Sustained 24-hour blockade of the renin-angiotensin system: A high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 2005;78:501-07.
43. Forclaz A., Maillard M., Nussberger J. et al. Angiotensin II receptor blockade: Is there truly a benefit of adding an ACE inhibitor? Hypertension 2003;41(1):31-6.
44. Le MT, Pugsley MK, Vauquelin G. et al. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol 2007;151:952-62.
45. Miura S., Fujino M., Hanzawa H. et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006;281:19288-95.
46. Chrysant S., Melino M., Karki S. et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604.
47. Neutel JM, Smith DH, Weber MA, Wang AC, Masonson HN Use of olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004;6:168-74.
48. Neutel JM, Smith DH, Silfani TN, Lee Y., Weber MA Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006;20:255-62.